Amyotrophic Lateral Sclerosis Treatment Market Size Worth $885.5 Million By 2026 | Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem

December 04 15:19 2019
Amyotrophic Lateral Sclerosis Treatment Market Size Worth $885.5 Million By 2026 | Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem

Grand View Research, Inc. – Market Research And Consulting.
Some of the key factors driving the amyotrophic lateral sclerosis treatment market include growing awareness about ALS, increasing incidence rate, and rising geriatric population. However, the cost associated with ALS treatment is high, which may hinder the market growth during the forecast period.

The global amyotrophic lateral sclerosis treatment market size is expected to reach USD 885.5 million by 2026, according to a new report by Grand View Research. Some of the key factors driving the market include growing awareness about ALS, increasing incidence rate, and rising geriatric population. However, the cost associated with ALS treatment is high, which may hinder the market growth during the forecast period.

Currently, no cure is available for ALS and treatments such as medications and stem cell therapies can only help to slow down the disease progression, manage the symptoms, and prevent unnecessary complications. Furthermore, inclination towards a sedentary lifestyle among the geriatric population increases the risk of developing the disorder that increases the demand for new targeted treatment options and therapeutic approaches. According to the U.S. Department of Health Resources & Services, the estimated prevalence of amyotrophic lateral sclerosis in the U.S. was 5.2 per 100,000 people and 16,583 cases of ALS were reported in 2015.

 North America amyotrophic lateral sclerosis treatment market size, by treatment, 2015 - 2026 (USD Million)

Get Details For “Sample Report, Detailed TOC, Segmentation & methodology of Amyotrophic Lateral Sclerosis Treatment Market” Click Link Below:

https://www.grandviewresearch.com/industry-analysis/amyotrophic-lateral-sclerosis-treatment-market

Treatment Insights

The treatment segment has been divided into medications, stem cell therapies and others. Among the treatments, the medication segment is anticipated to dominate the global ALS treatment market through the forecast period. There are only two drugs approved for the treatment of ALS, Rilutek (riluzole) and Radicava (edaravone). Another drug, Nuedexta (dextromethorphan/quinidine) has received FDA approval for the treatment pseudobulbar affect (PBA), a comorbidity of ALS.

Stem cell therapy is expected to show the highest CAGR due to the increasing demand of new approaches and advanced treatment options. Several initiatives have been taken by the government authoritative bodies and the Collaborative ALS Drug Discovery Initiative (CADDI) to fast-track development of novel drugs and treatments. This is expected to further boost the number of clinical trials and launch of pipeline drugs during the forecast period.

Europe amyotrophic lateral sclerosis treatment market share, by distribution channel, 2018 (%)

Would you Like to Take a Look On “Sample Report” of Amyotrophic Lateral Sclerosis Treatment Market Click the Link Below:

https://www.grandviewresearch.com/industry-analysis/amyotrophic-lateral-sclerosis-treatment-market/request/rs1

Among the treatments, the medications acquired the largest market share in 2018 and is expected to dominate the ALS market over the forecast period. Currently, only two drugs have been approved for use in ALS treatment, Rilutek (riluzole) and Radicava (edaravone). Nuedexta (dextromethorphan/quinidine) in another drug used in ALS treatments, however, it has been approved to treat the pseudobulbar affect (PBA), a comorbidity of ALS.  North America held the leading position in the amyotrophic lateral sclerosis market in 2018, while Asia Pacific is projected to grow the fastest among all regions through the forecast period.

Further Key Findings From the Study Suggest:

  • Medications held the largest market share in the treatment segment. Although, there is no cure for ALS, the approved medications such as riluzole and edaravone help in managing symptoms and delaying the disease progression.

  • Stem cell therapy is expected to demonstrate the highest CAGR among the treatment over the forecast period due to the increasing demand for new approaches and advanced treatment options

  • Asia Pacific regional market is projected to demonstrate the fastest growth during the forecast period due to rising disposable income and improving healthcare infrastructure

  • Some of the major companies operating in this market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.

Have Any Query? Ask Our Experts @ https://www.grandviewresearch.com/inquiry/6723/ibb

Grand View Research has segmented the ALS treatment market report on the basis of treatment, distribution channel, and region:

Treatment Outlook (Revenue, USD Million, 2015 – 2026)

  • Medication

  • Stem Cell Therapy

  • Others

Distribution Channel Outlook (Revenue, USD Million, 2015 – 2026)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

Regional Outlook (Revenue, USD Million, 2015 – 2026)

  • North America 

    • U.S.

    • Canada

  • Europe 

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific 

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

  • Latin America 

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 126 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 4126 analysts and consultants, the company adds 121200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 600 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/amyotrophic-lateral-sclerosis-treatment-market

  Categories: